Evaluation of quality of life for diverse patient populations

Yabroff, K. Robin; Bp, Linas

doi:10.1007/bf01806005

Cited by 19 publications

(9 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, however, additional data collection efforts have been ''piggybacked'' on these clinical trials in many areas in order to take advantage of these rich sources of data and to augment the knowledge gained from these studies. Particularly in Phases II and III cancer clinical trials, researchers have begun to invest heavily in the collection of both quality-of-life and economic data in order to more clearly understand the impact of therapy on these important domains [1][2][3][4][5][6].…”

mentioning

confidence: 99%

Beyond Efficacy and Effectiveness: Conducting Economic Analyses During Clinical Trials

et al. 2004

View full text Add to dashboard Cite

Few studies have examined cost issues in the field of dysphagia. This study presents cost data collected during a clinical trial in speech-language pathology, demonstrating the types of cost analyses that can be conducted and highlighting obstacles and issues facing investigators who seek to conduct economic analyses in this arena. Seventy-nine patients were enrolled in the clinical trial to assess the impact of a swallowing intervention on swallowing and speech function. The patients were at least one year past treatment for head and neck cancer. No significant intervention differences were detected in these outcomes. A companion economic analysis was conducted in 37 of these patients using patient diaries and followup with identified health care providers. Analyses indicated that (1) the intervention did not significantly reduce health care expenditures; (2) indirect costs and costs of hospitalizations are both important factors to consider during a trial; and (3) health care costs of this population are high relative to the rest of the U.S. population. Attrition from the overall study population can pose a serious threat to the viability of an economic study. The article concludes with a discussion of how these issues can be addressed in future studies.

show abstract

mentioning

confidence: 99%

Beyond Efficacy and Effectiveness: Conducting Economic Analyses During Clinical Trials

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Preferences for health states can be elicited from patients with disease (or their family members), from patients at risk for disease, or from the general public [17,18]. We elected to develop preferences from family members of children who currently had atopic dermatitis or were at risk for the disease.…”

Section: Methodsmentioning

confidence: 99%

Parents' reported preference scores for childhood atopic dermatitis disease states

et al. 2004

View full text Add to dashboard Cite

BackgroundWe sought to elicit preference weights from parents for health states corresponding to children with various levels of severity of atopic dermatitis. We also evaluated the hypothesis that parents with children who had been diagnosed with atopic dermatitis would assign different preferences to the health state scenarios compared with parents who did not have a child with atopic dermatitis.MethodsSubjects were parents of children aged 3 months to 18 years. The sample was derived from the General Panel, Mommies Sub-Panel, and Chronic Illness Sub-Panel of Harris Interactive. Participants rated health scenarios for atopic dermatitis, asthma, and eyeglasses on a visual analog scale, imagining a child was experiencing the described state.ResultsA total of 3539 parents completed the survey. Twenty-nine percent had a child with a history of atopic dermatitis. Mean preference scores for atopic dermatitis were as follows: mild, 91 (95% confidence interval [CI], 90.7 to 91.5); mild/moderate, 84 (95%CI, 83.5 to 84.4); moderate, 73 (95%CI, 72.5 to 73.6); moderate/severe, 61 (95%CI, 60.6 to 61.8); severe, 49 (95% CI, 48.7 to 50.1); asthma, 58 (95%CI, 57.4 to 58.8); and eyeglasses, 87(95%CI, 86.3 to 87.4).ConclusionsParents perceive that atopic dermatitis has a negative effect on quality of life that increases with disease severity. Estimates of parents' preferences can provide physicians with insight into the value that parents place on their children's treatment and can be used to evaluate new medical therapies for atopic dermatitis.

show abstract

“…Yet both class and cultural variation in the U.S. population represent significant conceptual and measurement challenges to routinely monitoring the quality of life of breast cancer patients. Yabroff et al [26] review the development, assess the quality, and discuss the application of different quality of life assessments to specific cultural groups.…”

Section: Patient Outcomesmentioning

confidence: 99%

Breast cancer prevention and control among the medically underserved

Kerner

1996

Breast Cancer Res Tr

View full text Add to dashboard Cite

In 1986, the National Cancer Institute published its cancer control objectives for the nation, which included projected reductions in breast cancer mortality. The reductions were estimated to be 25.0% from reducing fat, 16.0% from expanding use of breast cancer screening services, and 14.3% from expanding access to state-of-the-art breast cancer treatment. During the same decade, the U.S. population aged and became significantly more ethnically diverse, and accompanying this increase in ethnic diversity was endemic poverty, disproportionately experienced by black and Hispanic minorities. These populations may be seen as medically underserved. With respect to breast cancer, as well as many other cancers, the medically underserved are understudied, not well understood by many in the medical and academic research community, and attended by health care institutions that are under-funded and often do not have the resources necessary to ensure access to state-of-the-art cancer screening, clinical follow-up, diagnosis, and treatment. At the same time, medically underserved women are more likely to be diagnosed with late-stage breast cancer, and some groups (e.g. black women) bear the greatest breast cancer mortality burden in the nation. In this special issue of Breast Cancer Research and Treatment, eight papers describe what we know and what we don't about breast cancer prevention and control in medically underserved populations.

show abstract

Evaluation of quality of life for diverse patient populations

Cited by 19 publications

References 183 publications

Beyond Efficacy and Effectiveness: Conducting Economic Analyses During Clinical Trials

Beyond Efficacy and Effectiveness: Conducting Economic Analyses During Clinical Trials

Parents' reported preference scores for childhood atopic dermatitis disease states

Breast cancer prevention and control among the medically underserved

Contact Info

Product

Resources

About